Funded Startups in Or Yehuda
Among the 5 most recent Or Yehuda–based funded startups shown, Memic Innovative Surgery’s $96M round on 2021-04-12 is a clear disclosed outlier: it dwarfs…
Among the 5 most recent Or Yehuda–based funded startups shown, Memic Innovative Surgery’s $96M round on 2021-04-12 is a clear disclosed outlier: it dwarfs the next-largest disclosed amount, CORDIO Medical’s $23M on 2022-06-27, and sits far above Restore Medical’s $23M (2025-07-07) and Append Medical’s $4M (2023-07-06). The disclosed minimum is Append Medical at $4M, while one company (VeinWay, 2023-09-08) has an undisclosed amount.
Timing clusters are visible but uneven. Three of the disclosed rounds fall between 2022-06-27 and 2023-09-08 (CORDIO Medical, Append Medical, VeinWay), while the most recent entry is Restore Medical on 2025-07-07. Sector mix leans heavily toward life sciences: Biotechnology appears in 3 of the 5 rows (Restore Medical, Append Medical, Memic Innovative Surgery), with the remaining entries split across Health Care (VeinWay) and “Other” (CORDIO Medical).
Most recent rounds
5 shownRelated listings
Frequently asked
What are the largest and smallest disclosed rounds in Or Yehuda here, and how extreme is the gap?
Memic Innovative Surgery’s disclosed $96M (2021-04-12) is the largest amount shown, and it dwarfs the next-largest disclosed rounds at $23M (Restore Medical, 2025-07-07 and CORDIO Medical, 2022-06-27). The smallest disclosed amount is Append Medical’s $4M (2023-07-06).
Is there a concentration of deals in a narrow time window among these 5 most recent rows?
Three rounds land within roughly a year between 2022-06-27 and 2023-09-08: CORDIO Medical ($18M) on 2022-06-27, Append Medical ($4M) on 2023-07-06, and VeinWay (2023-09-08) with an undisclosed amount. Outside that window, Restore Medical closes much later on 2025-07-07 and Memic Innovative Surgery is earlier in 2021-04-12.
Do any sectors dominate this Or Yehuda list by count?
Biotechnology appears in 3 of the 5 rows: Restore Medical (Series B, 2025-07-07, $23M), Append Medical (Series A, 2023-07-06, $4M), and Memic Innovative Surgery (Series D, 2021-04-12, $96M). The other two rows are Health Care (VeinWay, 2023-09-08, undisclosed) and “Other” (CORDIO Medical, 2022-06-27, $18M).
How should the stage information be read across these companies, given unknown or undisclosed amounts?
Stages are not uniform: Biotechnology entries span Series B (Restore Medical, 2025-07-07, $23M) and Series D (Memic Innovative Surgery, 2021-04-12, $96M), while Append Medical is Series A (2023-07-06, $4M). Two records reduce comparability—VeinWay lists an undisclosed amount (2023-09-08) and CORDIO Medical is labeled “Venture - Series Unknown” (2022-06-27, $18M).
Which entries look like outliers beyond size, based on disclosed-vs-undisclosed and stage labeling?
VeinWay (2023-09-08) is an outlier on disclosure rather than magnitude because the amount is undisclosed, limiting any comparison to the disclosed $4M–$96M range. CORDIO Medical (2022-06-27, $18M) is another form of outlier due to its “Venture - Series Unknown” stage label rather than a named Series classification.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.